About Apica Cardiovascular

Apica Cardiovascular is a medical device company dedicated to establishing a new standard of care for transapical access and closure. The Company has developed a novel platform technology, which enables transapical delivery of aortic valves, mitral valves and other devices used in the treatment of Structural Heart Disease.
Read more...

News

2 July 2014 - THORATEC ACQUIRES APICA CARDIOVASCULAR
Thoratec Corporation (NASDAQ: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has acquired Apica Cardiovascular Limited (“Apica”)...
Read more...

2 December 2013 - "NUI Galway: Leading the way in cardiovascular procedures" - Irish Times
A novel medical device developed by Galway-based Apica Cardiovascular has the potential to revolutionise the delivery of different types of medical devices to the heart, including replacement valves. The access and closure device, which has successfully come through clinically trials and has been launched on the German market, offers a range of benefits, particularly to the mainly elderly patient population who undergo valve replacement surgery.
Read more...

11 November 2013: First Live Case with Innovative Transapical Access Technology at EACTS
The use of Apica’s innovative transapical access technology was successfully demonstrated for the first time at the 27th European Association for Cardio-Thoracic Surgery (EACTS) congress in Vienna. EACTS is one of the largest cardiac congresses in the world, with around 6,500 participants.
Read more...